Parameter
| Biomarker | NLR | Full name | Neutrophil-Lymphocyte Ratio | Molecular Type | Cell Ratio |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prognosis, Inflammation Assessment |
| Disease | Amyotrophic Lateral Sclerosis | Disease Subtypes | / | ||
| Organ | Brain | Test Sample / Technology Platform | Whole Blood (Hematology Analyzer) | ||
| Pathobiological Mechanisms | Enhanced systemic inflammatory response, increased neutrophils (pro-inflammatory), decreased lymphocytes (immunosuppression). | ||||
| Clinical Availability Status | Clinically available (routine testing) | ||||
| Notes and Dynamics | The survival period of patients with NLR >3 is 42% shorter than those with NLR <2, serving as a non-invasive prognostic indicator; positively correlated with disease progression rate. | ||||